Your browser doesn't support javascript.
loading
Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.
Klaeger, Susan; Apffel, Annie; Clauser, Karl R; Sarkizova, Siranush; Oliveira, Giacomo; Rachimi, Suzanna; Le, Phuong M; Tarren, Anna; Chea, Vipheaviny; Abelin, Jennifer G; Braun, David A; Ott, Patrick A; Keshishian, Hasmik; Hacohen, Nir; Keskin, Derin B; Wu, Catherine J; Carr, Steven A.
Afiliação
  • Klaeger S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Electronic address: sklaeger@broadinstitute.org.
  • Apffel A; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Clauser KR; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Sarkizova S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Oliveira G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rachimi S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Le PM; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Tarren A; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Chea V; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Abelin JG; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Braun DA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Ott PA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Keshishian H; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Hacohen N; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Keskin DB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Health Informatics Lab, Metropolitan College, Boston University, Boston, Massachusetts, USA.
  • Wu CJ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Carr SA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Electronic address: scarr@broad.mit.edu.
Mol Cell Proteomics ; 20: 100133, 2021.
Article em En | MEDLINE | ID: mdl-34391888
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Antígenos de Histocompatibilidade Classe I / Antígenos de Neoplasias Limite: Humans Idioma: En Revista: Mol Cell Proteomics Assunto da revista: BIOLOGIA MOLECULAR / BIOQUIMICA Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Antígenos de Histocompatibilidade Classe I / Antígenos de Neoplasias Limite: Humans Idioma: En Revista: Mol Cell Proteomics Assunto da revista: BIOLOGIA MOLECULAR / BIOQUIMICA Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos